The firm said the integration of AI mitigates background noise and enhances classification accuracy through a vast image database. Radhakrishnan said this innovation finds its purpose in addressing global challenges, specifically in the acute, chronic, and traumatic wound market, impacting 600 million individuals.
“Our flagship product, Illuminate, has yielded remarkable results, and we have screened over 10,000 patients since our launch last year,” said Radhakrishnan. “The solution has 92% accuracy and has prevented unnecessary antibiotic prescriptions and has improved wound healing rates.”
Another critical challenge that deep tech companies are addressing is traditional drug discovery. This is because it includes lengthy timelines, high costs, and failure rates. Hyderabad-based Centella AI Therapeutics' goal is to address this. It is using AI to accelerate timelines, reduce costs, improve success rates, and enable comprehensive data analysis. This way, it is transforming drug discovery into a more efficient, effective, and objective endeavor. The company said its easy-to-use and intelligent platform empowers drug hunters to leverage advanced tools without coding expertise. This digital transformation could result in cost reductions of up to 60%, coupled with a streamlined discovery timeline accelerated by approximately 25-45%. This not only brings efficiency but also enhances safety and efficacy while reducing the toxicity of drug-like candidates. The firm said this is paving the way for safer, faster, and more affordable drug candidates.